Norwegian ‘Oslo Patient’ Achieves Rare HIV Remission Following Stem Cell Transplant
A 63-year-old Norwegian man, now referred to as the “Oslo patient,” has become one of only a few individuals globally to achieve long-term remission from HIV. The breakthrough followed a bone marrow stem cell transplant from his brother, according to researchers from Oslo University Hospital.
The patient originally underwent an allogeneic hematopoietic stem cell transplantation (HSCT) to treat a rare form of blood cancer. During the process, researchers discovered that the patient’s brother possessed a rare genetic mutation known to resist HIV. This discovery allowed the medical team to closely monitor how the transplant affected the virus.
To determine the success of the procedure, scientists tracked “chimerism,” measuring the extent to which the donor’s blood and immune cells replaced the patient’s own. The results, published in Nat. Microbiol. (Myhre et al., 2026), revealed that all traces of functioning HIV DNA were cleared from the patient’s system four years after the transplant.
The patient was able to discontinue his HIV medications two years after the HSCT. As of five years post-transplant, there has been no evidence of viral rebound. This case provides critical evidence for the medical community, as it demonstrates a rare instance where the virus has been effectively suppressed without the need for ongoing drug therapy.
Whereas modern medications can control HIV by preventing the virus from replicating, they cannot completely eradicate it from the body; the virus typically rebounds as soon as treatment is stopped. Since of this, cases like the Oslo patient’s remission are invaluable for scientists working toward a definitive cure.
Researchers noted that this case, along with similar studies, enhances the global understanding of HIV pathology, molecular mechanisms, and predictive biomarkers. These insights may eventually offer benefits to a broader range of patients beyond those who undergo allogeneic HSCT.
The findings underscore the potential of genetic resistance in guiding future strategies for HIV eradication and highlight the ongoing importance of studying rare medical anomalies to advance public health.
